Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the ...

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...